Pennsylvania Convention Authority Renews ASM Global Management Contract Becoming First Venue in World Leader’s ‘Premier Package’ Convention Center Expansion
24.8.2023 23:46:00 EEST | Business Wire | Press release
The Pennsylvania Convention Center Authority (PCCA) board of directors has approved a five-year contract renewal for ASM Global as its venue management company with the convention center poised as the launch location for a dramatic series of innovations in ASM Global’s convention and conference portfolio — the largest in North America and worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824372126/en/
Photo courtesy of ASM Global.
The new agreement will commence on Dec. 1, 2023, for five years, through Nov. 30, 2028, with the international entertainment leader planning to bring many of its most innovative designs to a leading group of convention centers beginning with PCCA. It will be the first in a program creating unique environments such as immersive LED moments, speed-action offerings to accelerate business strategies, elevated VIP lounges and quiet spaces for business connectivity.
“We are thrilled to announce the continued partnership between the Pennsylvania Convention Center Authority and ASM Global as the venue-management provider for the Pennsylvania Convention Center,” said David A. Nasatir, Esq., chair of the board, PCCA. “For 10 years, ASM Global has been a valued collaborator and, because of their outstanding contributions, has elevated the Pennsylvania Convention Center to world-class status.”
In 2013 the PCCA first made the decision to privatize management of the center with an initial contract being awarded to SMG, which was subsequently rebranded to ASM Global following the 2019 merger of AEG Facilities and SMG. The merger created a venue management powerhouse that spans five continents, 14 countries and more than 350 of the world’s most prestigious arenas, stadiums, theaters and convention centers and has positioned ASM Global as the world’s preeminent venue-management and live-experiences company.
“The ASM Global team at the Pennsylvania Convention Center is, without exception, the finest in the industry,” said John J. McNichol, president and CEO, PCCA. “Their innovative leadership and commitment to delivering an unmatched customer experience have positioned the center, globally, as an industry trailblazer and venue of choice, and we look forward to continuing our collaboration as we take the Pennsylvania Convention Center to the next level.”
Under the management of ASM Global, the Pennsylvania Convention Center has already implemented several cutting-edge and industry-changing initiatives such as the 2014 execution of the Customer Satisfaction Agreement, a document that guides the relationship between the center and the labor unions that work at the facility with the goal of providing a more productive, customer-centric and cost-effective worksite for guests and the ASM Global Acts program, under which the center has successfully executed a robust sustainability and social impact plan.
Dan Hoffend, ASM Global executive vice president, convention centers, said, “We’re excited to begin the next chapter for the convention universe beginning with the Pennsylvania Convention Center. This includes sustainability features that create substantial movement toward carbon neutral; new Flex-space exhibit halls that can adapt to the needs of our diverse attendees; and LED walls that provide sponsorship, wayfinding and entertainment.
“We’re bringing our proven best features from our stadiums and arenas directly to our convention centers to create a premium line of facilities like no other in the industry. Our attendees require entertainment as a part of their business paradigm. We are changing the industry by creating a unique environment for all of our guests,” Hoffend said.
PCC’s ASM Global general manager, Tony Hodgins, said, “We thank the PCCA for their continued trust in our ASM Global team and for their unwavering support over the years. Our team at the center remains focused on our goal of providing a first-class customer experience to all our guests, and we are honored to be able to continue working with our key partners to showcase all that Philadelphia and the Pennsylvania Convention Center have to offer.”
For more information on the Pennsylvania Convention Center community-engagement and outreach initiatives, visit paconvention.com.
About Pennsylvania Convention Center
Pennsylvania Convention Center is located in Center City Philadelphia at the heart of the city's many cultural offerings and world-class dining and entertainment scene. Managed by ASM Global, the center is the 14th largest facility in the nation and features one of the largest exhibit spaces and ballrooms in the Northeastern U.S. The meetings, conventions, trade shows and other events hosted by the center attract attendees from across the country and around the world to Philadelphia, making the facility the largest economic driver of the region’s hospitality industry. For more information, visit paconvention.com.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management, delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook, Instagram, LinkedIn and Twitter. For more information, please visit asmglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230824372126/en/
Contact information
Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
818-264-6812
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom